November 12 · US market close
Biotechnology underperformed both broad healthcare and the S&P 500 in this session. The ETF returns show the size of the gap. The drivers of the move require separate evidence.
RWE@NAMTSO
November Healthcare Equities Report
US healthcare equities, company disclosures and the real-world evidence questions they raise.
Sources checked through · Toronto time
- XLV · Healthcare
- $187.83 close · −0.59%
- XBI · Biotechnology
- −3.28%
- IHI · Medical Devices
- $57.46 close
- SPY · S&P 500
- $757.12 close · −0.35%
November 12 regular-session closes in USD. Percentages are close-to-close price changes where shown. SPY is the broad-market benchmark.
Daily Update 每日更新
Belite Bio · BLTE
In its November 12 quarterly update, Belite Bio said tinlarebant remained under FDA priority review for Stargardt disease type 1, with a target action date of February 12, 2027. The date was first assigned in August.
Evidence Question 证据问题 How do trial eligibility and follow-up compare with the patients seen in routine care?
Company Developments 公司动态
Eli Lilly · LLY
October 29 earnings background. Q3 revenue rose 39% year over year to $24.4 billion, led by Mounjaro and Zepbound. Full-year revenue guidance increased to $91–92 billion.
Evidence Question 证据问题 How do access and treatment persistence vary in routine care?
Abbott · ABT
October 21 earnings background. Q3 device sales rose 6.9% as reported and 7.8% on a comparable basis. The release noted FDA approval of the Libre Duo glucose and ketone sensor.
Evidence Question 证据问题 What can post-launch data show about adoption and outcomes?
Medtronic · MDT
Fiscal Q2 2027 results are scheduled for November 24. Watch for organic growth by segment and changes to guidance.